LOS ANGELES--(BUSINESS WIRE)-- 8 November, 2012--Pivotal data from the RELY-ABLE® study have provided additional data to support the long-term safety profile and efficacy of Pradaxa® (dabigatran etexilate) for stroke prevention in patients with non-valvular atrial fibrillation (AF).*1 The new long-term results presented at the American Heart Association’s (AHA) Scientific Sessions, are highly consistent with the findings from the landmark RE-LY® trial+, based upon which the treatment was approved in countries all over the world. The rates of stroke and haemorrhage observed during the 2.3 years of blinded follow-up in RELY-ABLE® correspond to the initial RE-LY® results, supporting the benefit of both doses of Pradaxa® for tailored brain protection.1-3